Although sample size was small, the two dose cohorts demonstrated comparable anti-tumor activity
Although sample size was small, the two dose cohorts demonstrated comparable anti-tumor activity. abnormal hepatic function and coagulation tests, and upper gastrointestinal hemorrhage. The most common treatment-related adverse events were proteinuria, hypertension and diarrhea. Among 34 patients receiving sulfatinib formulation 2, one patient with hepatocellular carcinoma and eight with neuroendocrine tumors exhibited a partial response;…